CanSino Biologics (HKG:6185, SHA:688185) enrolled the first patient in its phase 1 clinical trial for its haemophilus influenzae type b freeze-dried conjugate vaccine.

The pathogen has two strains, one of which could cause otitis media or middle ear infection and sinusitis, and another which causes infections secondary to blood infections. It is most present in acute lower respiratory tract infections in children, the filing said.